| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537585 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| US11304961 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
Hemady is owned by Dexcel.
Hemady contains Dexamethasone.
Hemady has a total of 2 drug patents out of which 0 drug patents have expired.
Hemady was authorised for market use on 03 October, 2019.
Hemady is available in tablet;oral dosage forms.
Hemady can be used as a method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product.
The generics of Hemady are possible to be released after 18 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-271) | Oct 03, 2026 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET;ORAL
More Information on Dosage
HEMADY family patents
